Clinical Impact of the Presence of a Diffuse Large B-Cell Lymphoma (DLBCL) Component in the Outcome of Untreated Patients with Follicular Lymphoma (FL)

被引：0
|
作者：
Magnano, Laura
Dlouhy, Ivan
Balague, Olga
Rivas-Delgado, Alfredo
Rovira, Jordina
Karube, Kennosuke
Gonzalez, Blanca
Martinez-Trillos, Alejandra
Martinez, Antonio
Delgado, Julio
Gine, Eva
Villamor, Neus
Campo, Elias
Lopez-Guillermo, Armando
机构：
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3043.3043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3043
引用
收藏
页数：6
相关论文
共 50 条
  • [1] PATIENTS WITH FOLLICULAR LYMPHOMA (FL) SHOWING A DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) COMPONENT HAVE AN INTERMEDIATE OUTCOME BETWEEN FL AND DLBCL
    Magnano, L.
    Balague, O.
    Dlouhy, I.
    Rovira, J.
    Karube, K.
    Rivas, A.
    Gonzalez, B.
    Martinez-Trillos, A.
    Martinez, A.
    Delgado, J.
    Gine, E.
    Villamor, N.
    Campo, E.
    Lopez-Guillermo, A.
    HAEMATOLOGICA, 2016, 101 : 273 - 274
  • [2] Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma
    Magnano, L.
    Balague, O.
    Dlouhy, I.
    Rovira, J.
    Karube, K.
    Pinyol, M.
    Rivas-Delgado, A.
    Costa, D.
    Martinez-Trillos, A.
    Gonzalez-Farre, B.
    Martinez-Pozo, A.
    Gine, E.
    Colomer, D.
    Delgado, J.
    Villamor, N.
    Campo, E.
    Lopez-Guillermo, A.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2799 - 2805
  • [3] PRAMS Expression in Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL)
    Perez, M.
    Shafer, J. A.
    Curry, C.
    Zu, Y.
    Ewton, A.
    Dotti, G.
    Chang, C.
    MODERN PATHOLOGY, 2009, 22 : 280A - 281A
  • [4] PRAME Expression in Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL)
    Perez, M.
    Shafer, J. A.
    Curry, C.
    Zu, Y.
    Ewton, A.
    Dotti, G.
    Chang, C.
    LABORATORY INVESTIGATION, 2009, 89 : 280A - 281A
  • [5] Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL)
    Nowakowski, Grzegorz S.
    Maurer, Matthew J.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Macon, William R.
    Ristow, Kay M.
    Allmer, Cristme
    Stager, Susan L.
    Witzig, Thomas E.
    Cerhan, James R.
    BLOOD, 2008, 112 (11) : 219 - 219
  • [6] Activity and safety of ibrutinib and durvalumab in patients with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL)
    Herrera, A.
    Goy, A.
    Mehta, A.
    Ramchandren, R.
    Pagel, J.
    Svoboda, J.
    Guan, S.
    Hill, J.
    Kwei, K.
    Liu, E.
    Phillips, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E17 - E18
  • [7] Clinical impact of molecular features in diffuse large B-cell lymphoma and follicular lymphoma
    Pon, Julia R.
    Marra, Marco A.
    BLOOD, 2016, 127 (02) : 181 - 186
  • [8] Risk and clinical implications of transformation of follicular lymphoma (FL) to diffuse large cell B-cell lymphoma (tFL).
    Montoto, S
    Davies, AJ
    Matthews, J
    Calaminici, M
    Norton, AJ
    Amess, J
    Vinnicombe, S
    Rohatiner, AZS
    Lister, A
    BLOOD, 2005, 106 (11) : 179A - 179A
  • [9] Rituximab Fails to Reduce Histologic Transformation (HT) Rate of Follicular Lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL)
    Marciscano, Ariel E.
    Gupta, Neel
    Zhang, Zhigang
    Teruya-Feldstein, Julie
    Noy, Ariela
    BLOOD, 2008, 112 (11) : 310 - 310
  • [10] Diffuse large B-cell lymphoma (DLBCL)
    Renner, C.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 82 : S10 - S10
12345